I-Mab (Nasdaq:IMAB) - Hisse Senedi Fiyatı, Haberler ve Analizler

IMAB Stoklara Genel Bakış

IMAB temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( $80M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir geliri yok ( $3M )

Son 3 ayda dalgalı hisse senedi fiyatı

I-Mab Rakipler

Cibus

NasdaqCM:CBUS

US$117.4m

vTv Therapeutics

NasdaqCM:VTVT

US$46.5m

Shattuck Labs

NasdaqGS:STTK

US$53.0m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti I-Mab
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.96
52 Haftanın En Yüksek Seviyesi	US$2.54
52 Haftanın En Düşük Seviyesi	US$0.90
Beta	1.08
11 Aylık Değişim	-31.99%
3 Aylık Değişim	-21.07%
1 Yıllık Değişim	-36.07%
33 Yıllık Değişim	-98.52%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-92.33%

Son Haberler & Güncellemeler

Recent updates

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

Hissedar Getirileri

	IMAB	US Biotechs	US Pazar
7D	-10.4%	-3.7%	0.3%
1Y	-36.1%	15.2%	31.1%

Getiri vs. Endüstri: IMAB geçen yıl % 15.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: IMAB geçen yıl % 31.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IMAB's price volatile compared to industry and market?
IMAB volatility
IMAB Average Weekly Movement	12.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: IMAB hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IMAB 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	34	Sean Fu	ir.i-mabbiopharma.com

Klinik aşamada bir biyofarmasötik şirketi olan I-Mab, öncelikle Amerika Birleşik Devletleri'nde immüno-onkoloji ve immüno-inflamasyon hastalıkları alanlarında biyolojik ilaçlar keşfetmekte, geliştirmekte ve ticarileştirmektedir. Şirket, katı tümörlerin tedavisi için Faz 2 klinik çalışmasında olan CD73 nötralize edici bir antikor olan Uliledlimab'ı; mide ve diğer kanserlerin tedavisi için Faz 1 klinik çalışmasında olan bi-spesifik bir antikor olan Givastomig'i ve katı tümörlerin tedavisi için Faz 1 klinik çalışmasında olan programlanmış hücre ölümü ligand bazlı tümöre bağımlı bir T hücresi angajmanı olan Ragistomig'i geliştirmektedir. Şirket ayrıca kanser immünoterapisi için tamamen insan CD47 monoklonal antikoru olan Lemzoparlimab'ı geliştirme fırsatlarını değerlendirmektedir.

I-Mab Temel Bilgiler Özeti

I-Mab'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IMAB temel i̇stati̇sti̇kler
Piyasa değeri	US$79.81m
Kazançlar(TTM)	-US$202.50m
Gelir(TTM)	US$3.31m

23.6x

P/S Oranı

-0.4x

F/K Oranı

IMAB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IMAB gelir tablosu (TTM)
Gelir	US$3.31m
Gelir Maliyeti	US$0
Brüt Kâr	US$3.31m
Diğer Giderler	US$205.81m
Kazançlar	-US$202.50m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.49
Brüt Marj	100.00%
Net Kâr Marjı	-6,110.39%
Borç/Özkaynak Oranı	0%

IMAB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IMAB Stoklara Genel Bakış

Risk Analizi

I-Mab Rakipler

NasdaqCM:CBUS

US$117.4m

NasdaqCM:VTVT

US$46.5m

NasdaqGS:STTK

US$53.0m

NasdaqGS:FIXX

US$54.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

Recent updates

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency